30,700 Shares in BioNTech SE (NASDAQ:BNTX) Bought by Discovery Capital Management LLC CT

Discovery Capital Management LLC CT acquired a new stake in BioNTech SE (NASDAQ:BNTX) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 30,700 shares of the company’s stock, valued at approximately $2,467,000.

Other hedge funds also recently made changes to their positions in the company. Jump Financial LLC bought a new stake in BioNTech in the fourth quarter worth about $268,000. PNC Financial Services Group Inc. raised its holdings in shares of BioNTech by 207.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,583 shares of the company’s stock worth $273,000 after purchasing an additional 1,743 shares during the period. Wells Fargo & Company MN lifted its stake in BioNTech by 6.8% in the fourth quarter. Wells Fargo & Company MN now owns 82,171 shares of the company’s stock valued at $8,672,000 after purchasing an additional 5,227 shares during the last quarter. Franklin Resources Inc. grew its holdings in BioNTech by 166.3% during the fourth quarter. Franklin Resources Inc. now owns 9,892 shares of the company’s stock valued at $1,044,000 after purchasing an additional 6,177 shares during the period. Finally, US Bancorp DE grew its holdings in BioNTech by 420.7% during the fourth quarter. US Bancorp DE now owns 28,614 shares of the company’s stock valued at $3,020,000 after purchasing an additional 23,119 shares during the period. 15.52% of the stock is currently owned by institutional investors.

BioNTech Stock Down 0.2 %

Shares of BioNTech stock opened at $112.28 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The company’s 50 day moving average price is $90.81 and its 200-day moving average price is $90.62. The stock has a market capitalization of $26.69 billion, a price-to-earnings ratio of 224.56 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business’s revenue was down 23.3% on a year-over-year basis. During the same period last year, the company posted ($0.86) earnings per share. Equities research analysts forecast that BioNTech SE will post -2.8 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on BNTX shares. TD Cowen dropped their price target on BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. HSBC upgraded shares of BioNTech from a “hold” rating to a “buy” rating in a research note on Friday, August 2nd. UBS Group upped their price target on shares of BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th. Finally, Bank of America lifted their price objective on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $124.54.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.